ABBV vs. MRK: An Oncology-Immunology Showdown for Investors

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Competitive pressure might increase for Keytruda in the near future from dual PD-1/VEGF inhibitors like Summit Therapeutics' ivonescimab that are designed to overcome the limitations of single-target therapies like Keytruda

  80% confidence

• AbbVie is a clear-cut winner due to rising estimates, stock price appreciation, a solid pipeline and expectations for continued strong earnings growth

  80% confidence

• Merck faces several near-term challenges, including persistent challenges for Gardasil in China, potential competition for Keytruda and rising competitive and generic pressure on some of its drugs

  80% confidence

• AbbVie expects to outperform its target of combined sales of Skyrizi and Rinvoq of more than $25 billion in 2025 and more than $31 billion by 2027

  80% confidence

• AbbVie expected to return to mid-single-digit revenue growth in 2025 with a high single-digit CAGR through 2029, as it has no significant LOE events for the rest of this decade

  80% confidence

• There are rising concerns about Merck's ability to grow its non-oncology business ahead of the upcoming loss of exclusivity of Keytruda in 2028

  80% confidence

• Merck positioned to launch around 20 new vaccines and drugs over the next few years, with many having blockbuster potential

  80% confidence

Data points we hold from this source